Sandoz Canada announced the launch of PrSandoz Sitagliptin and PrSandoz Sitagliptin-Metformin. Monotherapy: These products are indicated as an additional therapy to improve glycemic control in adult patients with type 2 diabetes mellitus for whom current existing therapy, along with diet and exercise, does not provide adequate glycemic control. It is also used to help reduce long-term complications associated with the disease and help maintain quality of life over time.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVS:
- Novartis downgraded to Underweight from Equal Weight at Morgan Stanley
- Novartis upgraded to Neutral from Underweight at JPMorgan
- Novartis (NYSE:NVS) Could Loose $245M in Litigation Settlement
- Novartis to pay $245M to settle lawsuit on Exforge medicine, Bloomberg reports
- Sandoz Canada supports Ontario policy change on biosimilars